SWOG clinical trial number
SWOG-8228

Correlation Between Progesterone Receptor and Response to Tamoxifen in Patients with Newly Diagnosed Metastatic Breast Cancer

Closed
Phase
Published
Abbreviated Title
Correlation Between Progesterone Receptor and Response to Tamoxifen in Patients with Newly Diagnosed Metastatic Breast Cancer
Activated
09/17/1982
Closed
02/01/1987

Publication Information Expand/Collapse

1996

HER-2/neu expression does not predict response to tamoxifen in er-positive metastatic breast cancer.

R Elledge;S Green;D Ciocca;L Howes;R Pugh;G Clark;P Ravdin;J O'Sullivan;G Langone;CK Osborne Breast Cancer Research Treatment 41:289(#518)

1992

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study.

PM Ravdin;S Green;T Melink-Dorr;WL McGuire;C Fabian;RP Pugh;RD Carter;SE Rivkin;JR Borst;RJ Belt;B Metch;CK Osborne JCO 10(8):1284-1291

1990

Correlation between progesterone receptor (PgR) and response to tamoxifen in patients (PTS) with estrogen receptor (ER) positive newly diagnosed metastatic breast cancer. A Southwest Oncology Group study.

T Melink;S Green;B Metch;W McGuire;C Fabian;R Pugh;B Tranum;J Hill;CK Osborne ASCO 9:53(#202)

1984

Southwest Oncology Group experience with randomized protocols for bladder cancer.

JA Smith Jr;ED Crawford In: Controlled Clinical Trials in Urologic Oncology . L Denis, GP Murphy, GR Prout Jr, F Schroder, eds. New York: Raven Press 249-254